Skip to main content

Table 3 Rosiglitazone exposure at entry and hazard ratios for non-melanoma skin cancer

From: Rosiglitazone may reduce non-melanoma skin cancer risk in Taiwanese

Rosiglitazone use

Unadjusted

Age-sex-adjusted

Fully adjusted*

HR

95% CI

P

HR

95% CI

P

HR

95% CI

P

Ever users

0.882

(0.773, 1.005)

0.0602

0.908

(0.796, 1.036)

0.1513

0.927

(0.807, 1.066)

0.2865

Duration of therapy (months)

      

 <3.73

1.059

(0.861, 1.304)

0.5862

1.109

(0.901, 1.365)

0.3295

1.119

(0.905, 1.383)

0.2985

 3.73-13.77

0.903

(0.730, 1.118)

0.3507

0.941

(0.760, 1.165)

0.5744

0.961

(0.773, 1.196)

0.7243

 >13.77

0.703

(0.553, 0.893)

0.0039

0.705

(0.555, 0.896)

0.0043

0.723

(0.566, 0.923)

0.0094

 P-trend

  

0.0072

  

0.0171

  

0.0386

Cumulative dose (mg)

       

 <448

1.025

(0.830, 1.265)

0.8221

1.070

(0.867, 1.322)

0.5276

1.081

(0.872, 1.341)

0.4773

 448-1752

0.885

(0.713, 1.098)

0.2675

0.912

(0.735, 1.132)

0.4033

0.931

(0.747, 1.161)

0.5270

 >1752

0.752

(0.596, 0.948)

0.0157

0.764

(0.606, 0.963)

0.0228

0.783

(0.618, 0.993)

0.0436

 P-trend

  

0.0139

  

0.0337

  

0.0743

  1. Referent group: never-users of rosiglitazone; HR: hazard ratio, CI: confidence intervals.
  2. *Adjusted for all variables in Table 1.